Show simple item record

dc.contributor.authorJones, DTen
dc.contributor.authorLechertier, Ten
dc.contributor.authorMitter, Ren
dc.contributor.authorHerbert, JMJen
dc.contributor.authorBicknell, Ren
dc.contributor.authorJones, JLen
dc.contributor.authorLi, J-Len
dc.contributor.authorBuffa, Fen
dc.contributor.authorHarris, ALen
dc.contributor.authorHodivala-Dilke, Ken
dc.date.accessioned2017-11-27T15:34:37Z
dc.date.available2017-11-27T15:34:37Z
dc.date.issued2012en
dc.identifier.urihttp://hdl.handle.net/10026.1/10293
dc.description.abstract

Angiogenesis is essential for solid tumour growth, whilst the molecular profiles of tumour blood vessels have been reported to be different between cancer types. Although presently available anti-angiogenic strategies are providing some promise for the treatment of some cancers it is perhaps not surprisingly that, none of the anti-angiogenic agents available work on all tumours. Thus, the discovery of novel anti-angiogenic targets, relevant to individual cancer types, is required. Using Affymetrix microarray analysis of laser-captured, CD31-positive blood vessels we have identified 63 genes that are upregulated significantly (5-72 fold) in angiogenic blood vessels associated with human invasive ductal carcinoma (IDC) of the breast as compared with blood vessels in normal human breast. We tested the angiogenic capacity of a subset of these genes. Genes were selected based on either their known cellular functions, their enriched expression in endothelial cells and/or their sensitivity to anti-VEGF treatment; all features implicating their involvement in angiogenesis. For example, RRM2, a ribonucleotide reductase involved in DNA synthesis, was upregulated 32-fold in IDC-associated blood vessels; ATF1, a nuclear activating transcription factor involved in cellular growth and survival was upregulated 23-fold in IDC-associated blood vessels and HEX-B, a hexosaminidase involved in the breakdown of GM2 gangliosides, was upregulated 8-fold in IDC-associated blood vessels. Furthermore, in silico analysis confirmed that AFT1 and HEX-B also were enriched in endothelial cells when compared with non-endothelial cells. None of these genes have been reported previously to be involved in neovascularisation. However, our data establish that siRNA depletion of Rrm2, Atf1 or Hex-B had significant anti-angiogenic effects in VEGF-stimulated ex vivo mouse aortic ring assays. Overall, our results provide proof-of-principle that our approach can identify a cohort of potentially novel anti-angiogenic targets that are likley to be, but not exclusivley, relevant to breast cancer.

en
dc.format.extente44294 - ?en
dc.languageengen
dc.language.isoengen
dc.subjectAngiogenesis Inhibitorsen
dc.subjectAnimalsen
dc.subjectAntibodiesen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAorta, Thoracicen
dc.subjectBevacizumaben
dc.subjectBreast Neoplasmsen
dc.subjectCarcinoma, Ductal, Breasten
dc.subjectCell Line, Tumoren
dc.subjectFemaleen
dc.subjectGene Expression Profilingen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectIn Vitro Techniquesen
dc.subjectMiceen
dc.subjectMice, Inbred BALB Cen
dc.subjectMice, Inbred C57BLen
dc.subjectMice, SCIDen
dc.subjectMicroscopy, Confocalen
dc.subjectNeoplasms, Experimentalen
dc.subjectNeovascularization, Pathologicen
dc.subjectOligonucleotide Array Sequence Analysisen
dc.subjectPlatelet Endothelial Cell Adhesion Molecule-1en
dc.subjectRNA Interferenceen
dc.subjectTransplantation, Heterologousen
dc.subjectTumor Burdenen
dc.subjectVascular Endothelial Growth Factor Aen
dc.titleGene expression analysis in human breast cancer associated blood vessels.en
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/23056178en
plymouth.issue10en
plymouth.volume7en
plymouth.publication-statusPublisheden
plymouth.journalPLoS Oneen
dc.identifier.doi10.1371/journal.pone.0044294en
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/00 Groups by role
plymouth.organisational-group/Plymouth/00 Groups by role/Academics
plymouth.organisational-group/Plymouth/Faculty of Medicine and Dentistry
plymouth.organisational-group/Plymouth/Faculty of Medicine and Dentistry/Biomedical Research Group
plymouth.organisational-group/Plymouth/Faculty of Medicine and Dentistry/Biomedical Research Group/RC Reporting Group BRG
plymouth.organisational-group/Plymouth/Faculty of Medicine and Dentistry/Collaboration for the Advancement of Medical Education Research Assessment
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
dc.publisher.placeUnited Statesen
dcterms.dateAccepted2012-08-01en
dc.identifier.eissn1932-6203en
dc.rights.embargoperiodNot knownen
rioxxterms.versionofrecord10.1371/journal.pone.0044294en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2012en
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
@mire NV